A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme)

Table 1 Plausible case mix conditions

% expected response in standard arm	# patients	% expected response in experimental arm	Relative risk (experimental vs standard)
35	201	54,8 %	1,57
30	209	49,1 %	1,63
25	230	42,9 %	1,71

ISSN: 1471-2407